Drug intelligence / Profile preview

Plagentic

Development stage: Unknown
Lead developer: Koru Pharma
Administration: Subcutaneous, Intramuscular, Topical

Overview

Plagentic is a placenta-derived cosmetic and therapeutic product developed by Koru Pharmaceuticals. Its primary active ingredient is human placenta extract, which contains a concentrated blend of amino acids, minerals, and other nutritional compounds. The product is designed to promote cellular restoration and repair by normalizing metabolism within tissue layers and optimizing nutrient uptake. It is indicated for skin rejuvenation and the treatment of conditions such as atopic dermatitis and herpes recidivicus. Plagentic is typically supplied in ampule form for professional administration, primarily via subcutaneous or intramuscular injection.

Brand names: Plagentic
Other names: human placenta extract

Beyond the preview

Go deeper on Plagentic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plagentic.

Explore the full profile